Sanofi Aventis Us patents expiration
1. Ambien Cr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6514531 | SANOFI AVENTIS US | Controlled-release dosage forms comprising zolpidem or a salt thereof |
Dec, 2019
(4 years ago) | |
|
US6514531 (Pediatric) | SANOFI AVENTIS US | Controlled-release dosage forms comprising zolpidem or a salt thereof |
Jun, 2020
(3 years ago) | |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 02 September, 2005
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
AMBIEN CR family patents
2. Apidra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6221633 | SANOFI AVENTIS US | Insulin derivatives having a rapid onset of action |
Jun, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7452860 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Mar, 2022
(2 years ago) | |
| US7696162 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Mar, 2022
(2 years ago) | |
| US6960561 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Jan, 2023
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: Method of treating a patient suffering from diabetes mellitus
Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
APIDRA family patents
3. Apidra Solostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6221633 | SANOFI AVENTIS US | Insulin derivatives having a rapid onset of action |
Jun, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7696162 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Mar, 2022
(2 years ago) | |
| US7452860 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Mar, 2022
(2 years ago) | |
| US6960561 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Jan, 2023
(1 year, 2 months ago) | |
| US9610409 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(a month ago) | |
| US9775954 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(a month ago) | |
| US8603044 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(a month ago) | |
| US9604008 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(a month ago) | |
| US9526844 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(a month ago) | |
| US9408979 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(a month ago) | |
| US9233211 | SANOFI AVENTIS US | Relating to a pen-type injector |
Mar, 2024
(a month ago) | |
| US9827379 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(a month ago) | |
| US8556864 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(a month ago) | |
| US9011391 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(29 days ago) | |
| US8992486 | SANOFI AVENTIS US | Pen-type injector |
Jun, 2024
(a month from now) | |
| US9604009 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9533105 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9623189 | SANOFI AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9561331 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(4 months from now) | |
| US8512297 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2024
(4 months from now) | |
| US8679069 | SANOFI AVENTIS US | Pen-type injector |
Apr, 2025
(11 months from now) | |
| US7918833 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2027
(3 years from now) | |
| US9717852 | SANOFI AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: Method of treating a patient suffering from diabetes mellitus; Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glyce...
Dosage: INJECTABLE;SUBCUTANEOUS
APIDRA SOLOSTAR family patents
4. Aubagio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5459163 | SANOFI AVENTIS US | Medicament to combat autoimmune diseases |
Oct, 2012
(11 years ago) | |
| US5679709 | SANOFI AVENTIS US | Medicaments to combat autoimmune diseases |
Oct, 2014
(9 years ago) | |
| US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(2 years from now) | |
|
US6794410 (Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(2 years from now) | |
| US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(6 years from now) | |
|
US8802735 (Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(6 years from now) | |
| US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(9 years from now) | |
|
US9186346 (Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Apr 30, 2024 |
| Pediatric Exclusivity(PED) | Oct 30, 2024 |
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction...
Dosage: TABLET;ORAL
AUBAGIO family patents
5. Avalide patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5994348 | SANOFI AVENTIS US | Pharmaceutical compositions containing irbesartan |
Jun, 2015
(8 years ago) | |
|
US5994348 (Pediatric) | SANOFI AVENTIS US | Pharmaceutical compositions containing irbesartan |
Dec, 2015
(8 years ago) | |
Drugs and Companies using HYDROCHLOROTHIAZIDE; IRBESARTAN ingredient
Market Authorisation Date: 30 September, 1997
Treatment: NA
Dosage: TABLET;ORAL
AVALIDE family patents
6. Avapro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6342247 | SANOFI AVENTIS US | Pharmaceutical compositions containing irbesartan |
Jun, 2015
(8 years ago) | |
|
US6342247 (Pediatric) | SANOFI AVENTIS US | Pharmaceutical compositions containing irbesartan |
Dec, 2015
(8 years ago) | |
Drugs and Companies using IRBESARTAN ingredient
Market Authorisation Date: 30 September, 1997
Treatment: NA
Dosage: TABLET;ORAL
AVAPRO family patents
7. Eloxatin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5290961 | SANOFI AVENTIS US | Platinum compound and process of preparing same |
Jan, 2013
(11 years ago) | |
| US5338874 | SANOFI AVENTIS US | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity |
Apr, 2013
(11 years ago) | |
| US5420319 | SANOFI AVENTIS US | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same |
Aug, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5290961 (Pediatric) | SANOFI AVENTIS US | Platinum compound and process of preparing same |
Jul, 2013
(10 years ago) | |
|
US5338874 (Pediatric) | SANOFI AVENTIS US | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity |
Oct, 2013
(10 years ago) | |
| US5716988 | SANOFI AVENTIS US | Pharmaceutically stable preparation of oxaliplatinum |
Aug, 2015
(8 years ago) | |
|
US5716988 (Pediatric) | SANOFI AVENTIS US | Pharmaceutically stable preparation of oxaliplatinum |
Feb, 2016
(8 years ago) | |
|
US5420319 (Pediatric) | SANOFI AVENTIS US | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same |
Feb, 2017
(7 years ago) | |
Drugs and Companies using OXALIPLATIN ingredient
Market Authorisation Date: 31 January, 2005
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
ELOXATIN family patents
8. Jevtana Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6331635 | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar, 2016
(8 years ago) | |
| US5847170 | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar, 2021
(3 years ago) | |
| US7241907 | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Dec, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5698582 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
| US5438072 | SANOFI AVENTIS US | Taxoid-based compositions |
Nov, 2013
(10 years ago) | |
| US6387946 | SANOFI AVENTIS US | Methods for treating pathological conditions of abnormal cell proliferation |
Mar, 2016
(8 years ago) | |
| US6372780 | SANOFI AVENTIS US | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
Mar, 2016
(8 years ago) | |
|
US5847170 (Pediatric) | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Sep, 2021
(2 years ago) | |
|
US7241907 (Pediatric) | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Jun, 2026
(2 years from now) | |
| US8927592 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
| US10583110 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
| US10716777 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
|
US8927592 (Pediatric) | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Apr, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-209) | Sep 14, 2020 |
| M(M-201) | May 17, 2020 |
| M(M-128) | Dec 18, 2023 |
| Pediatric Exclusivity(PED) | Nov 17, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2015 |
Drugs and Companies using CABAZITAXEL ingredient
NCE-1 date: 18 November, 2019
Market Authorisation Date: 17 June, 2010
Treatment: Treatment of cancer; Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen t...
Dosage: SOLUTION;INTRAVENOUS
JEVTANA KIT family patents
9. Ketek patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5635485 | SANOFI AVENTIS US | Erythromycin compounds |
Apr, 2018
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USD459798 | SANOFI AVENTIS US | Pill tablet |
Sep, 2015
(8 years ago) | |
Drugs and Companies using TELITHROMYCIN ingredient
Market Authorisation Date: 09 February, 2005
Treatment: Treatment of community acquired pneumonia, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis caused by susceptible strains of designated microorganisms in patients 18 years and o...
Dosage: TABLET;ORAL
KETEK family patents
10. Lantus patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5656722 | SANOFI AVENTIS US | A21 -, B30 - modified insulin derivatives having an altered action profile |
Aug, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5656722 (Pediatric) | SANOFI AVENTIS US | A21 -, B30 - modified insulin derivatives having an altered action profile |
Feb, 2015
(9 years ago) | |
| US7713930 | SANOFI AVENTIS US | Acidic insulin preparations having improved stability |
Jun, 2023
(10 months ago) | |
| US7476652 | SANOFI AVENTIS US | Acidic insulin preparations having improved stability |
Jul, 2023
(9 months ago) | |
|
US7713930 (Pediatric) | SANOFI AVENTIS US | Acidic insulin preparations having improved stability |
Dec, 2023
(4 months ago) | |
|
US7476652 (Pediatric) | SANOFI AVENTIS US | Acidic insulin preparations having improved stability |
Jan, 2024
(3 months ago) | |
| US7918833 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2027
(3 years from now) | |
|
US7918833 (Pediatric) | SANOFI AVENTIS US | Pen-type injector |
Mar, 2028
(3 years from now) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Treatment of diabetes mellitus
Dosage: INJECTABLE;INJECTION
LANTUS family patents
11. Lantus Solostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9610409 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(a month ago) | |
| US9233211 | SANOFI AVENTIS US | Relating to a pen-type injector |
Mar, 2024
(a month ago) | |
| US9408979 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(a month ago) | |
| US9526844 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(a month ago) | |
| US9827379 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(a month ago) | |
| US9604008 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(a month ago) | |
| US8603044 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(a month ago) | |
| US9775954 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(a month ago) | |
| US8556864 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(a month ago) | |
| US9011391 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(29 days ago) | |
| US8992486 | SANOFI AVENTIS US | Pen-type injector |
Jun, 2024
(a month from now) | |
| US9604009 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9533105 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9623189 | SANOFI AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9561331 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(4 months from now) | |
| US8512297 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2024
(4 months from now) | |
| US8679069 | SANOFI AVENTIS US | Pen-type injector |
Apr, 2025
(11 months from now) | |
| US9717852 | SANOFI AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glycemic control in diabetes mellitus patients by use of a pen injec...
Dosage: INJECTABLE;INJECTION
LANTUS SOLOSTAR family patents
12. Multaq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5223510 | SANOFI AVENTIS US | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them |
Jul, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8318800 | SANOFI AVENTIS US | Solid pharmaceutical compositions containing benzofuran derivatives |
Jun, 2018
(5 years ago) | |
| US7323493 | SANOFI AVENTIS US | Solid pharmaceutical composition containing benzofuran derivatives |
Jun, 2018
(5 years ago) | |
| US9107900 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
Apr, 2029
(4 years from now) | |
| US8410167 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Apr, 2029
(4 years from now) | |
| US8602215 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
Jun, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2014 |
Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient
NCE-1 date: 01 July, 2013
Market Authorisation Date: 01 July, 2009
Treatment: Reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning a...
Dosage: TABLET;ORAL
MULTAQ family patents
13. Nasacort Aq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5976573 | SANOFI AVENTIS US | Aqueous-based pharmaceutical composition |
Jul, 2016
(7 years ago) | |
| US6143329 | SANOFI AVENTIS US | Aqueous-based pharmaceutical composition |
Jul, 2016
(7 years ago) | |
| US7977045 | SANOFI AVENTIS US | Aqueous-based pharmaceutical composition |
Jul, 2016
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 19, 2011 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 20 May, 1996
Treatment: Treatment of seasonal and perennial allergic rhinitis symptoms; Treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adults and children two years of age and older
Dosage: SPRAY, METERED;NASAL
NASACORT AQ family patents
14. Oforta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7547776 | SANOFI AVENTIS US | Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5% |
Dec, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7148207 | SANOFI AVENTIS US | Oral fludara of high-purity formulation with quick release of active ingredient |
Dec, 2022
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 18, 2011 |
| Orphan Drug Exclusivity(ODE) | Dec 18, 2015 |
Drugs and Companies using FLUDARABINE PHOSPHATE ingredient
Market Authorisation Date: 18 December, 2008
Treatment: Treatment of patients with b-cell chronic lymphocytic leukemia (cll)
Dosage: TABLET;ORAL
OFORTA family patents
15. Plavix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6504030 | SANOFI AVENTIS US | Polymorphic form of clopidogrel hydrogen sulphate |
Jun, 2019
(4 years ago) | |
| US6429210 | SANOFI AVENTIS US | Polymorphic clopidogrel hydrogenesulphate form |
Jun, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6504030 (Pediatric) | SANOFI AVENTIS US | Polymorphic form of clopidogrel hydrogen sulphate |
Dec, 2019
(4 years ago) | |
|
US6429210 (Pediatric) | SANOFI AVENTIS US | Polymorphic clopidogrel hydrogenesulphate form |
Dec, 2019
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | May 06, 2014 |
| Pediatric Exclusivity(PED) | Nov 06, 2014 |
Drugs and Companies using CLOPIDOGREL BISULFATE ingredient
Market Authorisation Date: 17 November, 1997
Treatment: NA
Dosage: TABLET;ORAL
PLAVIX family patents
16. Taxotere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5714512 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
| US5698582 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
| US5750561 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
|
US5750561 (Pediatric) | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jan, 2013
(11 years ago) | |
|
US5714512 (Pediatric) | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jan, 2013
(11 years ago) | |
|
US5698582 (Pediatric) | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jan, 2013
(11 years ago) | |
| US5438072 | SANOFI AVENTIS US | Taxoid-based compositions |
Nov, 2013
(10 years ago) | |
|
US5438072 (Pediatric) | SANOFI AVENTIS US | Taxoid-based compositions |
May, 2014
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Nov 13, 2013 |
| M(M-61) | May 13, 2013 |
Drugs and Companies using DOCETAXEL ingredient
Market Authorisation Date: 03 August, 2010
Treatment: NA
Dosage: INJECTABLE;INJECTION
TAXOTERE family patents